| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00436-012-3212-3 |
| P698 | PubMed publication ID | 23239091 |
| P50 | author | Poonam Salotra | Q28869475 |
| Shyam Sundar | Q58941021 | ||
| P2093 | author name string | Louis Maes | |
| Jean Claude Dujardin | |||
| Rupkatha Mukhopadhyay | |||
| Syamal Roy | |||
| V Ramesh | |||
| Vasundhra Bhandari | |||
| Arpita Kulshrestha | |||
| P2860 | cites work | Advances in leishmaniasis | Q29617229 |
| Visceral leishmaniasis control: a public health perspective | Q34115722 | ||
| Advances in the treatment of leishmaniasis | Q35160721 | ||
| In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity | Q37072017 | ||
| Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. | Q39335886 | ||
| In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent | Q39444290 | ||
| Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). | Q39444314 | ||
| In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences | Q41844113 | ||
| Miltefosine affects lipid metabolism in Leishmania donovani promastigotes | Q42067834 | ||
| Treatment of Visceral Leishmaniasis in 2010: Direction From Bihar State, India | Q42879827 | ||
| Evaluation of hydrogen peroxide-based disinfectants in a new resazurin microplate method for rapid efficacy testing of biocides | Q46080622 | ||
| A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. | Q50506555 | ||
| Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. | Q51765295 | ||
| Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis. | Q52669939 | ||
| Evidence that the High Incidence of Treatment Failures in Indian Kala‐Azar Is Due to the Emergence of Antimony‐Resistant Strains ofLeishmania donovani | Q56781882 | ||
| Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis | Q59003574 | ||
| Post-kala-azar dermal leishmaniasis | Q72210953 | ||
| P433 | issue | 2 | |
| P921 | main subject | miltefosine | Q411787 |
| Leishmania donovani | Q1950752 | ||
| promastigote | Q106395109 | ||
| P304 | page(s) | 825-828 | |
| P577 | publication date | 2012-12-13 | |
| P1433 | published in | Parasitology Research | Q15755242 |
| P1476 | title | Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani | |
| P478 | volume | 112 |
| Q38088424 | (Post-) Genomic approaches to tackle drug resistance in Leishmania. |
| Q41874952 | Achievement of constitutive fluorescent pLEXSY-egfp Leishmania braziliensis and its application as an alternative method for drug screening in vitro |
| Q36237748 | Cyclobenzaprine Raises ROS Levels in Leishmania infantum and Reduces Parasite Burden in Infected Mice. |
| Q28550454 | Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India |
| Q39014583 | Evaluating drug resistance in visceral leishmaniasis: the challenges |
| Q93167639 | Evaluation of synergy between host and pathogen-directed therapies against intracellular Leishmania donovani |
| Q46921246 | Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum |
| Q37225817 | In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis |
| Q33797614 | Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress |
| Q28285948 | Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance |
| Q39063747 | Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome |
| Q39462738 | Leishmanicidal Activity and Structure-Activity Relationships of Essential Oil Constituents |
| Q57293286 | Lipase precursor like protein promotes miltefosine tolerance in by enhancing parasite infectivity and eliciting anti-inflammatory responses in host macrophages |
| Q91975125 | Miltefosine-Lopinavir Combination Therapy Against Leishmania infantum Infection: In vitro and in vivo Approaches |
| Q24611966 | Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain |
| Q59801068 | Second-generation pterocarpanquinones: synthesis and antileishmanial activity |
| Q39020376 | Susceptibility Testing of Medically Important Parasites |
| Q88574829 | Susceptibility of promastigotes and intracellular amastigotes from distinct Leishmania species to the calpain inhibitor MDL28170 |
Search more.